SymKardia
Westlake, US · Founded 2024 · Delaware corporation
Find your way into SymKardia
135 people in our graph share verified history with the SymKardia team — schools, employers, funds. One of them is your warm intro.
Will Bruneunlockedknows Dwight Skinner · together at Case Western Reserve University
×11knows the team · via Case Western Reserve University
SymKardia develops a selective cardiac neuromodulation therapy to treat cardiac arrhythmias such as atrial fibrillation, targeting the nervous system rather than only cardiac tissue. It is a clinical-stage cardiovascular medical device company running pre-clinical and clinical research programs.
Founders & leadership
SG
Steven GirouardExecutive
JP
Jonathan PicciniExecutive
DS
Dwight SkinnerinChief Operating OfficerDwight Skinner has over 25 years of experience in medical device product development, with expertise in implantable electrical stimulation systems, cardiac leads, and neuromodulation therapies. He holds a Design for Six Sigma Master Black Belt certification and brings knowledge of regulatory and manufacturing standards including ISO 10993 biocompatibility and MRI safety.
IL
Imad LibbusChief Scientific Officer
BK
Bruce KenKnightChief Executive Officer
AC
Anthony CaparsoExecutive
Board
RP
Robert PicarelBoard director
CR
Claudio RumazzaBoard director
AS
Arun SridharBoard director
AG
Alain Garcinuno ColletBoard director
JB
James BlouzardBoard director
Reported raises · per SEC filings
Form D private placements$500K disclosed across 1 round · 2026
▶$500KraisedJun 2026 · 1 investors · Other Health CareRule 506(b)
▶$500KraisedJun 2026 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Robert PicarelDirector
- Steven GirouardExecutive Officer
- Claudio RumazzaDirector
- Jonathan PicciniExecutive Officer
- Dwight SkinnerExecutive Officer
- Imad LibbusExecutive Officer
- Arun SridharDirector
- Bruce KenKnightExecutive Officer
- Anthony CaparsoExecutive Officer, Director
- Alain Garcinuno ColletDirector
- James BlouzardDirector
- Offering amount
- $4M
- Amount sold
- $500K
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapBioworld21 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Rf Surgical21 shared keywordsMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Syncardia14 shared keywordsSynCardia manufactures the world's first commercially approved total artificial heart for patients with end-stage heart failure awaiting transplant. The company develops and delivers mechanical circulatory support devices as alternatives to heart transplantation for critically ill patients.
Companies competing with SymKardia for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does SymKardia do?
- SymKardia develops a selective cardiac neuromodulation therapy to treat cardiac arrhythmias such as atrial fibrillation, targeting the nervous system rather than only cardiac tissue. It is a clinical-stage cardiovascular medical device company running pre-clinical and clinical research programs.
- How much funding has SymKardia raised?
- SymKardia has disclosed $500K raised across 1 round.
- Where is SymKardia headquartered?
- SymKardia is headquartered in Westlake, US.